Company Overview
Snapshot
Founded in January 2018, Scentech Medical operates with 1–10 employees, focusing on breath diagnostic technology. The company is currently in the Pre-Funding stage. In August 2021, Scentech Medical signed a cooperation agreement with the Biological Institute, signaling a strategic move for its technology development.
Business overview
Scentech Medical develops non-invasive, real-time screening solutions for infectious diseases, providing instant results through a simple breath test. The company's core technology detects unique metabolic processes associated with pathogens, creating a singular metabolic fingerprint for each. This enables Scentech Medical's Rapid Scent Test to identify various pathogens, even in early, asymptomatic stages of infection. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices, targeting healthcare providers with its diagnostic solutions.
Strategic signal
In February 2022, Scentech Medical underwent a leadership change, bringing in the former director of the Biological Institute to move the company forward. This strategic personnel shift suggests an effort to strengthen leadership and potentially accelerate development or market entry, particularly following earlier reports of the company's technology not being mature enough for investment.
Log in to access full profile ›Company Intelligence Q&A
- What is Scentech Medical's primary focus?
- Scentech Medical focuses on developing non-invasive, real-time breath diagnostic technology for the screening of infectious diseases, aiming to provide instant results.
- When did Scentech Medical begin early tests for its COVID-19 breathalyzer detector?
- In April 2020, Scentech Medical began early tests for its breathalyzer detector designed to identify COVID-19.
- What was a key development for Scentech Medical in August 2021?
- In August 2021, Scentech Medical signed a cooperation agreement with the Biological Institute, ahead of a potential merger with NextGen.
- What significant clinical trial did NextGen announce in January 2021 related to Scentech Medical's technology?
- In January 2021, NextGen announced a clinical trial for a rapid breath test for COVID-19 detection, which also aimed to evaluate the efficacy of vaccines, including the Pfizer-BioNTech vaccine.
- What strategic change occurred at Scentech Medical in February 2022?
- In February 2022, Scentech Medical made a leadership change, bringing in the former director of the Biological Institute, to help facilitate a potential merger.